TRDA vs. IDYA, MESO, AGIO, APGE, AMPH, TARS, IOVA, IRON, IBRX, and WVE
Should you be buying Entrada Therapeutics stock or one of its competitors? The main competitors of Entrada Therapeutics include IDEAYA Biosciences (IDYA), Mesoblast (MESO), Agios Pharmaceuticals (AGIO), Apogee Therapeutics (APGE), Amphastar Pharmaceuticals (AMPH), Tarsus Pharmaceuticals (TARS), Iovance Biotherapeutics (IOVA), Disc Medicine (IRON), ImmunityBio (IBRX), and Wave Life Sciences (WVE). These companies are all part of the "pharmaceutical products" industry.
Entrada Therapeutics vs.
Entrada Therapeutics (NASDAQ:TRDA) and IDEAYA Biosciences (NASDAQ:IDYA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, analyst recommendations, community ranking, dividends, valuation, earnings and profitability.
Entrada Therapeutics has higher revenue and earnings than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.
Entrada Therapeutics presently has a consensus target price of $25.67, indicating a potential upside of 102.26%. IDEAYA Biosciences has a consensus target price of $53.67, indicating a potential upside of 141.96%. Given IDEAYA Biosciences' higher possible upside, analysts plainly believe IDEAYA Biosciences is more favorable than Entrada Therapeutics.
Entrada Therapeutics has a beta of -0.12, meaning that its share price is 112% less volatile than the S&P 500. Comparatively, IDEAYA Biosciences has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500.
In the previous week, IDEAYA Biosciences had 7 more articles in the media than Entrada Therapeutics. MarketBeat recorded 8 mentions for IDEAYA Biosciences and 1 mentions for Entrada Therapeutics. Entrada Therapeutics' average media sentiment score of 1.67 beat IDEAYA Biosciences' score of -0.03 indicating that Entrada Therapeutics is being referred to more favorably in the media.
86.4% of Entrada Therapeutics shares are held by institutional investors. Comparatively, 98.3% of IDEAYA Biosciences shares are held by institutional investors. 7.6% of Entrada Therapeutics shares are held by insiders. Comparatively, 3.5% of IDEAYA Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
IDEAYA Biosciences received 123 more outperform votes than Entrada Therapeutics when rated by MarketBeat users. However, 81.82% of users gave Entrada Therapeutics an outperform vote while only 71.57% of users gave IDEAYA Biosciences an outperform vote.
Entrada Therapeutics has a net margin of 25.53% compared to IDEAYA Biosciences' net margin of 0.00%. Entrada Therapeutics' return on equity of 16.11% beat IDEAYA Biosciences' return on equity.
Summary
Entrada Therapeutics beats IDEAYA Biosciences on 11 of the 18 factors compared between the two stocks.
Get Entrada Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TRDA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Entrada Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:TRDA) was last updated on 1/21/2025 by MarketBeat.com Staff
